Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Company Deals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Fineline Cube Mar 13, 2026
Policy / Regulatory

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL

Fineline Cube Mar 16, 2026
Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Fineline Cube Mar 16, 2026
Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market

Fineline Cube Mar 16, 2026
Company Deals

Shanghai Ark Biopharmaceutical’s STAR Market IPO Filing Accepted, Aims to Raise $289.6 Million

Fineline Cube Apr 21, 2023

Shanghai Ark Biopharmaceutical Co., Ltd’s Initial Public Offering (IPO) filing to the Shanghai Stock Exchange’s...

Company Drug

Hunan Warrant Pharmaceutical Receives NMPA Approval for Generic Brivudine

Fineline Cube Apr 21, 2023

Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving marketing...

Company Drug

Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC

Fineline Cube Apr 21, 2023

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III...

Company Deals

Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine’s HIV Drugs

Fineline Cube Apr 21, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...

Company Medical Device

Acotec Scientific’s Vericor-14 Microcatheter Receives NMPA Approval for Vascular Surgeries

Fineline Cube Apr 21, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Drug

Janssen’s Spravato Approved by NMPA for Adult Depression and Suicidal Ideation Treatment

Fineline Cube Apr 21, 2023

Janssen’s Spravato (esketamine) has been granted approval by the National Medical Products Administration (NMPA) in...

Company Drug

Jiangxi Jemincare Group Secures Clinical Trial Approvals for Four Innovative Drugs

Fineline Cube Apr 21, 2023

Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced receiving clinical trial approvals for four...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial

Fineline Cube Apr 21, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...

Company Deals Drug

Legend Biotech’s Carvykti Data Boosts Stock Price by 19.64% on Positive Phase III Results

Fineline Cube Apr 20, 2023

Shares of Legend Biotech (NASDAQ: LEGN) jumped an impressive 19.64% in a single day, attributed...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approval for Paclitaxel-Coated Balloon Dilation Catheter

Fineline Cube Apr 20, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Drug

CARSgen Therapeutics’ CT041 Receives NMPA Approval for Post-Operative Pancreatic Cancer Therapy

Fineline Cube Apr 20, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist, CARSgen Therapeutics Holdings Ltd (HKG: 2171), has announced...

Company Drug

Zelgen Biopharmaceuticals’ ZG2001 Receives NMPA Approval for Clinical Trials

Fineline Cube Apr 20, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Drug

Beijing Aosaikang’s ASKG915 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Apr 20, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...

Company Drug

InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for Recurrent/Refractory MZL Treatment

Fineline Cube Apr 20, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving another indication approval from the...

Company Drug

Walvax Biotechnology’s RQ3013 mRNA Vaccine Shows Efficacy in Phase III Study

Fineline Cube Apr 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the efficacy interim results of a...

Policy / Regulatory

NMPA’s 2022 Drug Supervision Report: Clinical Trials and Market Filings on the Rise

Fineline Cube Apr 20, 2023

The National Medical Products Administration (NMPA) has released its “Annual Drug Supervision and Administration Statistics...

Company Medical Device

Alcon Laboratories’ Innovative Intraocular Lens Approved by China’s NMPA

Fineline Cube Apr 20, 2023

The National Medical Products Administration (NMPA) has granted import approval to US firm Alcon Laboratories,...

Company Drug

Biosyngen Receives US FDA IND Approval for T-Cell Redirection Therapy for EBV-Positive Lymphoma

Fineline Cube Apr 19, 2023

Biosyngen Pte Ltd, a cell and gene therapy (CGT) biotech with operations in Singapore and...

Company Deals

EOC Pharma Group Partners with China National Accord Medicines for Distribution Rights

Fineline Cube Apr 19, 2023

China-based EOC Pharma Group has announced a strategic partnership with compatriot firm China National Accord...

Company Deals

Ubrigene Secures RMB 150 Million in Series C+ Financing to Expand Global CGT CDMO Platform

Fineline Cube Apr 19, 2023

Yiming Cell Biotechnology Co., Ltd, known as Ubrigene Biosciences Inc., a leading gene and cell...

Posts pagination

1 … 503 504 505 … 634

Recent updates

  • Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine
  • 3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market
  • Chipscreen Biosciences’ CS08399 Wins NMPA Approval – PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas
  • China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL
  • Novartis’ Cosentyx Wins FDA Pediatric Approval – Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market

Company Drug

Chipscreen Biosciences’ CS08399 Wins NMPA Approval – PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas

Policy / Regulatory

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.